InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.41
(
0.25%
)
US TECH 100
18,241.60
(
0.05%
)
Dow Jones
39,872.99
(
0.17%
)
Brent Oil
81.60
(
-1.03%
)
Bitcoin
69,906.26
(
-0.32%
)
Post# of 251888
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: pcrutch post# 161932

Tuesday, 06/04/2013 6:05:56 AM

Tuesday, June 04, 2013 6:05:56 AM

Post# of 251888

The biomarker data on using PDL1 staining doesn't help them since it doesn't appear to be all that predictive.

PDL-1 expression status was found in some trials to be related to response to anti PD-1 mAb (see for example http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200690 ). However, it is a problematic biomarker in many aspects and as noted in the recent NEJM paper, combination of Nivo+Yervoy makes this biomarker and also absolute lymphocyte counts (that was found to be associated with response to Yervoy), not relevant. I believe this also goes for a prior treatment with Yervoy.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up